Diabetes
1 – 50 of 67
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice
(
- Contribution to journal › Article
- 2023
-
Mark
Ethnic, gender and other sociodemographic biases in genome-wide association studies for the most burdensome non-communicable diseases : 2005-2022
(
- Contribution to journal › Article
-
Mark
Contribution of GIP and GLP-1 to the Insulin Response to Oral Administration of Glucose in Female Mice
(
- Contribution to journal › Article
-
Mark
Gut hormone-based pharmacology : novel formulations and future possibilities for metabolic disease therapy
(
- Contribution to journal › Scientific review
-
Mark
Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin following Ingestion of Different Classes of Macronutrients
(
- Contribution to journal › Article
-
Mark
Alternative splicing encodes functional intracellular CD59 isoforms that mediate insulin secretion and are down-regulated in diabetic islets
(
- Contribution to journal › Article
-
Mark
Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function : Review on Mathematical Modelling Approaches
(
- Contribution to journal › Scientific review
-
Mark
Novel Subgroups of Type 2 Diabetes Display Different Epigenetic Patterns, Which Associate With Future Diabetic Complications
(
- Contribution to journal › Article
-
Mark
The Glucose Sensitivity of Insulin Secretion-Lessons from In Vivo and In Vitro Studies in Mice
(
- Contribution to journal › Article
-
Mark
Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion : The human literature revisited and a systematic study in model experiments in mice
(
- Contribution to journal › Article
- 2021
-
Mark
Glucose effectiveness : Lessons from studies on insulin-independent glucose clearance in mice
(
- Contribution to journal › Scientific review
-
Mark
The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice : Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice
(
- Contribution to journal › Article
-
Mark
Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice
(
- Contribution to journal › Article
-
Mark
Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test
(
- Contribution to journal › Article
-
Mark
Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice
(
- Contribution to journal › Article
-
Mark
Glucose-lowering action through targeting islet dysfunction in type 2 diabetes : Focus on dipeptidyl peptidase-4 inhibition
(
- Contribution to journal › Scientific review
-
Mark
Hepatic and extrahepatic insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors
(
- Contribution to journal › Article
-
Mark
The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice
(
- Contribution to journal › Article
- 2020
-
Mark
Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes
(
- Contribution to journal › Article
-
Mark
The incretin effect in female mice with double deletion of GLP-1 and GIP receptors
(
- Contribution to journal › Article
-
Mark
Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men
(
- Contribution to journal › Article
-
Mark
On Meal Effects and DPP-4 Inhibition Islet- and Incretin Hormones in Health and Type 2 Diabetes
2020) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
- 2019
-
Mark
Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice
2019) In American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 316(1). p.27-37(
- Contribution to journal › Article
-
Mark
Glucagon-like peptide-1 receptor agonists for type 2 diabetes : A rational drug development
(
- Contribution to journal › Article
-
Mark
Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections
(
- Contribution to journal › Article
-
Mark
Islet adaptation in GIP receptor knockout mice
2019) In Peptides(
- Contribution to journal › Scientific review
-
Mark
Glucagon Counter-Regulation to Hypoglycemia During Incretin-Based Therapy
(
- Thesis › Doctoral thesis (monograph)
-
Mark
Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
(
- Contribution to journal › Article
-
Mark
DPP-4 inhibition and the path to clinical proof
(
- Contribution to journal › Article
-
Mark
Insulin and incretin hormone responses to rapid versus slow ingestion of a standardized solid breakfast in healthy subjects.
(
- Contribution to journal › Article
-
Mark
Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5).
(
- Contribution to journal › Article
-
Mark
Reductioninglycatedhemoglobin and daily insulin dose alongside circadian clock upregulation in patients with type 2 diabetes consuming a three-meal diet : A randomized clinical trial
(
- Contribution to journal › Article
- 2018
-
Mark
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
(
- Contribution to journal › Article
-
Mark
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients
(
- Contribution to journal › Article
-
Mark
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
(
- Contribution to journal › Article
-
Mark
Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects
(
- Contribution to journal › Article
- 2017
-
Mark
Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice
(
- Contribution to journal › Article
-
Mark
Albiglutide for the treatment of type 2 diabetes mellitus : An integrated safety analysis of the HARMONY phase 3 trials
(
- Contribution to journal › Article
-
Mark
Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus : Results over 52 weeks
(
- Contribution to journal › Article
-
Mark
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus : Long-term efficacy with or without rescue therapy
(
- Contribution to journal › Article
-
Mark
Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide : effects alone and in combination on insulin secretion and glucose disappearance in mice
(
- Contribution to journal › Article
-
Mark
Influences of breakfast on clock gene expression and postprandial glycemia in healthy individuals and individuals with diabetes : A randomized clinical trial
(
- Contribution to journal › Article
-
Mark
The vildagliptin experience - 25 years since the initiation of the novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration
(
- Contribution to journal › Article
-
Mark
High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA1C in Type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2) : a 56-week, double-blind, phase 3a, randomised trial
(
- Contribution to journal › Article
- 2016
-
Mark
CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion
(
- Contribution to journal › Article
-
Mark
Increased expression of the diabetes gene SOX4 reduces insulin secretion by impaired fusion pore expansion
(
- Contribution to journal › Article
-
Mark
Serotonin (5-HT) and 5-HT2A receptor agonists suppress lipolysis in primary rat adipose cells
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes : The adjunct two randomized trial
(
- Contribution to journal › Article